Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eprenetapopt + pegylated liposomal doxorubicin
- Development stage
- Phase 2
- Lead developer
- Aprea Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Eprenetapopt + pegylated liposomal doxorubicin** is a combination therapy under investigation for cancer treatment. \n- **Eprenetapopt (APR-246)** is a small molecule that reactivates mutant p53 protein, restoring its tumor suppressor function and inducing apoptosis in cancer cells. \n- **Pegylated liposomal doxorubicin** is a chemotherapy drug in which doxorubicin is encapsulated in pegylated liposomes; this formulation prolongs circulation time, enhances tumor delivery via the enhanced permeability and retention effect, and reduces exposure to healthy tissues. Doxorubicin, an anthracycline, inhibits topoisomerase 2, leading to DNA damage and cancer cell death[1][2][4]. \nThe combination is studied primarily in hematological malignancies and solid tumors.
- Other names
- APR-246APR246APR 246PRIMA-1METPRIMA1METPRIMA 1METeprenetapoptpegylated liposomal doxorubicindoxorubicin HCl liposomePLD
02
Targets
DNATOP2A (DNA topoisomerase II)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on eprenetapopt + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eprenetapopt + pegylated liposomal doxorubicin.